Literature DB >> 22921042

Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables.

Madhusmita Behera1, John J Heine, Gabriel L Sica, Erin E Fowler, Ha Tran, Robert W Fu, Anthony A Gal, Robert Hermann, William Mayfield, Fadlo R Khuri, Taofeek K Owonikoko, Suresh S Ramalingam.   

Abstract

BACKGROUND: Lung cancer is the leading cause of cancer-related mortality. Understanding patient attributes that enhance survival and predict recurrence is necessary to individualize treatment options.
METHODS: Patients (N = 162) were dichotomized into favorable (n = 101) and unfavorable (n = 61) groups based on survival characteristics. Ku86 and poly(ADP-ribose) polymerase (PARP) expression measures were incorporated into the analyses. LR, Kaplan-Meier analysis, and Cox regression were used to investigate intervariable relationships and survival. Odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess associations.
RESULTS: Sex (OR, 0.32; CI-0.14, 0.76), squamous cell carcinoma (SCC) (OR, 0.41; CI-0.17, 0.98), and recurrence (OR, 0.04; CI-0.01, 0.20) confer an unfavorable outcome with area under the receiver operating characteristic curve (Az) = 0.788. Patients with increased tumor grade (OR = 1.84; CI-1.06, 3.19) or increased Ku86 intensity (OR, 2.03; CI-1.08, 3.82) were more likely to be male individuals, and older patients (OR, 1.70; CI-(1.14, 2.52) were more likely to have SCC. Patients older than the median age (HR, 1.86; CI-1.11, 3.12), patients with SCC (HR, 1.78; CI-1.05, 3.01), patients with recurrence (HR, 4.16; CI-2.37, 7.31), and male patients (HR, 2.03; CI-1.20, 3.43) have a higher hazard. None of the DNA repair measures were associated with significant HRs.
CONCLUSION: Clinical and pathologic factors that enhance and limit survival for patients with stage I NSCLC were quantified. The DNA repair measures showed little association. These findings are important given that certain clinical and pathologic features are related to better long-term survival outcome than others.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22921042      PMCID: PMC5787388          DOI: 10.1016/j.cllc.2012.06.001

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  15 in total

Review 1.  Adjuvant chemotherapy in completely resected non-small-cell lung cancer.

Authors:  Katherine M W Pisters; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544

2.  International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.

Authors:  Susan S Devesa; Freddie Bray; A Paloma Vizcaino; D Max Parkin
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

3.  Molecular staging for survival prediction of colorectal cancer patients.

Authors:  Steven Eschrich; Ivana Yang; Greg Bloom; Ka Yin Kwong; David Boulware; Alan Cantor; Domenico Coppola; Mogens Kruhøffer; Lauri Aaltonen; Torben F Orntoft; John Quackenbush; Timothy J Yeatman
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

4.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

5.  Racial/Ethnic disparities and geographic differences in lung cancer incidence --- 38 States and the District of Columbia, 1998-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-11-12       Impact factor: 17.586

6.  Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe.

Authors:  M L Janssen-Heijnen; J W Coebergh
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

7.  Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.

Authors:  S-H Ignatius Ou; Jason A Zell; Argyrios Ziogas; Hoda Anton-Culver
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 9.  Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.

Authors:  Edward F Patz; Stephen J Swensen; James E Herndon
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data.

Authors:  Madhusmita Behera; Erin E Fowler; Taofeek K Owonikoko; Walker H Land; William Mayfield; Zhengjia Chen; Fadlo R Khuri; Suresh S Ramalingam; John J Heine
Journal:  Biomed Eng Online       Date:  2011-11-08       Impact factor: 2.819

View more
  1 in total

1.  HPV-associated lung cancers: an international pooled analysis.

Authors:  Camille Ragin; Monisola Obikoya-Malomo; Sungjin Kim; Zhengjia Chen; Rafael Flores-Obando; Denise Gibbs; Chihaya Koriyama; Francisco Aguayo; Jill Koshiol; Neil E Caporaso; Giovanna E Carpagnano; Marco Ciotti; Hirotoshi Dosaka-Akita; Masashi Fukayama; Akiteru Goto; Demetrios A Spandidos; Vassilis Gorgoulis; Daniëlle A M Heideman; Robert A A van Boerdonk; Kenzo Hiroshima; Reika Iwakawa; Nikolaos G Kastrinakis; Ichiro Kinoshita; Suminori Akiba; Maria T Landi; H Eugene Liu; Jinn-Li Wang; Ranee Mehra; Fadlo R Khuri; Wan-Teck Lim; Taofeek K Owonikoko; Suresh Ramalingam; Emmanuela Sarchianaki; Kari Syrjanen; Ming-Sound Tsao; Jenna Sykes; Siew Wan Hee; Jun Yokota; Apostolos Zaravinos; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2014-02-12       Impact factor: 4.944

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.